Jason J. Luke, M.D., F.A.C.P. is an Assistant Professor of Medicine at the University of Chicago where he specializes in the management of patients with melanoma and early phase drug development (particularly novel immunotherapeutics and biomarkers of immunotherapy activity). Dr. Luke has been a lead national investigator on clinical trials of immunotherapy agents including but not limited to anti-PD1/L1, CTLA4, LAG3, TIM3, GITR, OX40, CD137, CD40, inhibitors of indolamine-dioxygenase (IDO), adenosine A2a receptor and arginase as well as agonists of STING and oncolytic virus. Dr. Luke’s major research translational research is focused on using large scale informatics to advance the field of cancer immunotherapy. Dr. Luke received his M.D. from Rosalind Franklin University of Medicine and Science in Chicago. He then pursued internship and residency at the Boston University Medical Center followed by medicine and medical oncology fellowships at Weill Cornell Medical College and Memorial Sloan-Kettering Cancer Center in New York City. Following fellowship, Dr. Luke was a tenure-track, Type 1 Instructor in Medicine at Harvard Medical School as well as Staff Physician at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital in Boston. Dr. Luke is actively involved in several professional societies including the Society for Melanoma Research, the Society for Immunotherapy of Cancer, American Association for Cancer Research and the American Society for Clinical Oncology (ASCO). Dr. Luke has served as the chair of the education committee and as a member of the scientific committee for the melanoma track of the ASCO annual meeting. Dr. Luke has received several awards including the Melanoma Research Foundation Humanitarian Award, Department of Defense Career Development Award, Paul Calabresi Career Development in Clinical Oncology Award (K12), ASCO Merit Award as well as Young Investigator Awards from the Melanoma Research Alliance, the Cancer Research Foundation and the Conquer Cancer Foundation of ASCO. Dr. Luke’s research has been supported by ASCO, the National Comprehensive Cancer Network and the National Cancer Institute.